Financial reports
10-Q
2016 Q1
Quarterly report
10 May 16
10-K/A
2015 FY
Annual report (amended)
29 Apr 16
10-K
2015 FY
Annual report
29 Mar 16
NT 10-K
Notice of late annual filing
15 Mar 16
10-Q
2015 Q3
Quarterly report
16 Nov 15
10-Q
2015 Q2
Quarterly report
12 Aug 15
10-Q
2015 Q1
Quarterly report
13 May 15
10-K
2014 FY
Annual report
31 Mar 15
10-Q
2014 Q3
Quarterly report
10 Nov 14
10-Q
2014 Q2
Quarterly report
11 Aug 14
Current reports
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1 Aug 16
8-K
Entry into a Material Definitive Agreement
25 Jul 16
8-K
Entry into a Material Definitive Agreement
1 Jul 16
8-K
Entry into a Material Definitive Agreement
14 Jun 16
8-K
EPIRUS Announces Reprioritization of Pipeline to Solely Focus on Biosimilars to Treat Rare Diseases and Key Leadership Changes
9 May 16
8-K
EPIRUS Biopharmaceuticals Reports Fourth Quarter and Fiscal Year 2015 Financial Results and Provides Business Update
15 Mar 16
8-K
Entry into a Material Definitive Agreement
1 Mar 16
8-K
Other Events
9 Feb 16
8-K
EPIRUS Biopharmaceuticals Reports Third Quarter 2015 Financial ResultsĀ & Provides Business Update
16 Nov 15
8-K/A
Completion of Acquisition or Disposition of Assets
16 Nov 15
Registration and prospectus
25-NSE
Exchange delisting
26 Sep 16
S-8
Registration of securities for employees
29 Mar 16
424B5
Prospectus supplement for primary offering
1 Mar 16
S-3
Shelf registration
1 Jul 15
S-8
Registration of securities for employees
1 Jul 15
424B5
Prospectus supplement for primary offering
30 Jan 15
S-3MEF
Registration of additional securities for an S-3
29 Jan 15
424B5
Prospectus supplement for primary offering
26 Jan 15
S-8
Registration of securities for employees
11 Aug 14
425
Business combination disclosure
2 Jul 14
Proxies
DEF 14A
Definitive proxy
24 Apr 15
DEFA14A
Additional proxy soliciting materials
24 Apr 15
PRE 14A
Preliminary proxy
14 Apr 15
SC 14F1
Statement regarding change in majority of directors
27 Jun 14
DEFA14A
Additional proxy soliciting materials
9 May 14
DEF 14A
Definitive proxy
29 Apr 13
PRER14A
Preliminary revised proxy
19 Apr 13
PRE 14A
Preliminary proxy
11 Apr 13
DEF 14A
Definitive proxy
24 Apr 12
DEF 14A
Definitive proxy
15 Apr 11
Other
REVOKED
Registration or securities revoked
15 May 24
CT ORDER
Confidential treatment order
22 Dec 15
EFFECT
Notice of effectiveness
17 Jul 15
CORRESP
Correspondence with SEC
16 Jul 15
UPLOAD
Letter from SEC
9 Jul 15
CT ORDER
Confidential treatment order
13 Jan 15
CT ORDER
Confidential treatment order
3 Oct 14
EFFECT
Notice of effectiveness
6 Jun 14
CORRESP
Correspondence with SEC
5 Jun 14
UPLOAD
Letter from SEC
23 May 14
Ownership
SC 13G/A
EPIRUS Biopharmaceuticals, Inc.
14 Feb 17
SC 13G/A
EPIRUS Biopharmaceuticals, Inc.
11 Jul 16
SC 13G/A
EPIRUS Biopharmaceuticals, Inc.
11 Jul 16
SC 13G/A
EPIRUS Biopharmaceuticals, Inc.
8 Jul 16
4
Michael Wyand
31 May 16
4
Robert Ticktin
31 May 16
4
Vincent Aurentz
31 May 16
4
Thomas A. Shea
31 May 16
4/A
Michael Wyand
11 Mar 16
4
Amit Munshi
1 Mar 16